Classics and Rare Innovation Shine at Lucky Car Collector Auctions
⚡️ Read the full article on Motorious
Lucky Car Collector Auctions' upcoming event will showcase a rich array of postwar American innovation and design, with a spotlight on six exceptionally rare and distinctive classics from the 1940s through the 1960s. Each vehicle represents a unique story of mid-century engineering, luxury, or creative ambition—traits that continue to fascinate collectors and enthusiasts today.
Lot #152 – 1955 Nash Ambassador Country Club
A rare 2-door hardtop from Nash's golden era, this Ambassador Country Club is one of fewer than 1,800 produced and is believed to be one of the finest surviving examples. Powered by a Packard Jetfire 320 V8 and mated to a Packard Ultramatic transmission, this air-conditioned Nash features Pininfarina styling and a completely restored interior with authentic fabrics. With just over 41,000 believed-original miles and extensive mechanical upkeep, it's a stunning testament to George Mason's vision and the early days of American Motors.
Lot #198 – 1956 Nash Statesman
While details are pending, this Nash Statesman is expected to present another appealing slice of mid-century Americana. Known for value and comfort, Statesmans offered quality engineering and were key players in Nash's transition into AMC.
Lot #145 – 1953 Nash-Healey Roadster by Pinin Farina
An early example of transatlantic collaboration, this Nash-Healey Roadster is one of only 160 bodied by Pinin Farina in 1953. Retaining its numbers-matching engine and chassis, it represents a fascinating blend of British engineering, Italian design, and American power. With racing pedigree and Hollywood cachet, this project-ready classic is a potential showstopper in the right hands.
Lot #196 – 1949 Frazer Manhattan Convertible Sedan
A true rarity, this Frazer Manhattan Convertible is one of only 62 ever produced and among the very few survivors. Winner of a Kaiser-Frazer National Gold Award and restored to factory specs in Caribbean Coral, this six-cylinder luxury sedan exemplifies early postwar elegance and remains ready for concours or comfortable cruising.
Lot #171 – 1963 Studebaker Lark Wagonaire Regal
Dubbed one of the earliest crossovers, the Studebaker Wagonaire wowed buyers with its retractable roof design—big enough for a refrigerator, according to period ads. This Regal-trim example sports a 289ci V8 and a column-shifted manual transmission. With unique design flair and mechanical dependability, it remains an eye-catching oddity ready to drive.
Lot #131 – 1954 Kaiser Manhattan
Powered by a supercharged 226ci six and one of only 1,200 built for 1954, this Kaiser Manhattan embodies the automaker's fight for relevance in a tough market. Featuring a McCulloch VS-57 supercharger and GM Hydramatic transmission, this well-maintained survivor has been both show and road worthy in recent years. Recently serviced brakes and working electrics (minus the clock) make it an excellent candidate for continued enjoyment or full restoration.
#147 1948 Kaiser Custom Sedan
This 1948 Kaiser Custom Sedan is a true one-off, originally built for Edgar Kaiser—son of industrialist Henry Kaiser—while he served as general manager of the Kaiser-Frazer Corporation. Assembled at the Willow Run plant in Ypsilanti, Michigan, this special-order vehicle featured every luxury option available at the time, plus several bespoke elements unique to the boss's car.
Each of these cars not only offers rarity but also a tangible connection to the ambition and inventiveness of America's independent automakers. Lucky's auction is shaping up to be a celebration of vehicles that dared to do things differently—and are all the more collectible for it.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
32 minutes ago
- The Hill
Puerto Rico is Trump's perfect partner in reshoring
President Trump recently signed an executive order to bring pharmaceutical manufacturing back to the U.S. by streamlining the process for the Food and Drug Administration to approve pharmaceutical manufacturing plants. This is the latest in the Trump administration's agenda to protect national security and create American jobs by promoting the reshoring of critical supply chains that Americans rely on every day. These efforts are coupled with international tariffs to encourage domestic manufacturing. Reshoring pharmaceutical manufacturing is not only dire for American national security, but it could have resounding economic impacts across the country. One U.S. jurisdiction that is ready and in a perfect position to partner in this effort is Puerto Rico, where pharmaceutical manufacturing is already a more than $50 billion industry. With complementary efforts underway in Congress and on the island, the White House should look to Puerto Rico as America's pharmaceutical powerhouse while not trapping the island in its current territory status by hindering a future transition to statehood that would further boost the island's manufacturing ability. As a territory, the island is part of the U.S. customs zone and is not subject to U.S. tariffs, and everything that is made in Puerto Rico is 'Made in the USA.' Yet, that same territory status has limited Puerto Rico's economic development by creating persistent uncertainty, underinvestment and an unequal playing field for economic competition. The territory status is unpopular on the island, and Puerto Rican voters have voted in favor of statehood four consecutive times, most recently last November. Trump and Congress have the opportunity of a generation to leverage the pharmaceutical infrastructure and workforce in Puerto Rico to achieve their agenda while also turbocharging the economy on the island, and they have the perfect ally in Puerto Rico to do it with — the island's Republican Gov. Jenniffer González-Colón. González-Colón is leading an ambitious agenda to reshape the national narrative about the island and its people — and ultimately achieve statehood for Puerto Rico. Aligning with the Trump administration's vision to reshore advanced manufacturing of critical products, she issued an executive order in late March and reached out to top White House officials to offer Puerto Rico's well-established, yet currently underutilized, manufacturing capacity as an economic engine to help grow American prosperity. González-Colón's executive order promotes the relocation of overseas manufacturing of pharmaceuticals and other products to Puerto Rico. Much like Trump's executive order, it eliminates barriers and streamlines the process for businesses to move to the island. This action is complementary to the Medical Manufacturing, Economic Development and Sustainability Act, which was recently reintroduced and incentivizes pharmaceutical manufacturing on the island and throughout economically distressed zones across the United States. The bill is designed to attract business to the island in a way that invests in the people of Puerto Rico. It does this by providing an incentive for medical manufacturing facilities to relocate to economically distressed zones, with an incentive dependent on the number of jobs created to ensure money is flowing back into communities. The incentive itself is based on economic factors and applies to communities throughout the United States — an appropriately wide scope that comports with Trump's strong desire to reshore large amounts of production in a short time frame. By tethering the tax credits to what manufacturers invest directly into wages, salaries and real middle-class benefits, the proposal creates good-paying, quality American jobs. Reshoring to Puerto Rico would mean that critical pharmaceuticals and medical devices, as well as other products that are currently manufactured overseas in China and other nations, would now be produced in America. This would create thousands of well-paying manufacturing jobs that Puerto Rico needs to turbocharge the modest economic progress it's made in recent years. The increased consumer demand on the island would help boost the approximately $70 billion in annual interstate commerce, resulting in more jobs and profits stateside. Puerto Rico is a natural partner in reshoring the medical and pharmaceutical manufacturing industry within U.S. borders. The island's leaders share in the White House's vision of a more prosperous pharmaceutical manufacturing industry and are working to ensure reshoring efforts do not trap Puerto Rico in its current territory status but instead enable it to reach its full potential as an engine of economic growth and prosperity as a future state of our Union. Manufacturing makes America stronger, especially when it lifts up communities and the hard-working American citizens that make 'Made in the USA' a possibility, including those in Puerto Rico.
Yahoo
an hour ago
- Yahoo
Cooper Companies Second Quarter 2025 Earnings: EPS Misses Expectations
Revenue: US$1.00b (up 6.3% from 2Q 2024). Net income: US$87.7m (down 1.3% from 2Q 2024). Profit margin: 8.7% (down from 9.4% in 2Q 2024). The decrease in margin was driven by higher expenses. EPS: US$0.44 (down from US$0.45 in 2Q 2024). AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 39%. Looking ahead, revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US. Performance of the American Medical Equipment industry. The company's shares are down 13% from a week ago. While earnings are important, another area to consider is the balance sheet. See our latest analysis on Cooper Companies' balance sheet health. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
The Hill
2 hours ago
- The Hill
Business leaders are reshaping Washington and delivering for taxpayers
President Trump's historic comeback victory included a mandate from the American people to reform the federal government. The inefficiencies of our broken bureaucracy are all too apparent to everyday Americans, and it was a big reason why they hired a new administration that specifically ran on fixing the system. Americans know the problems our government faces today are urgent and require immediate action. They have watched as the federal bureaucracy has exploded in size and as their tax dollars are wasted on frivolous spending. All of us realize that maintaining our current course is no longer sustainable. We are trillions of dollars in debt, and steadily approaching a point of no return. As Americans cut costs and work tirelessly to balance their own budgets after four years of economic uncertainty, they are now rightly demanding that the federal government do the same. But like the old cliche about the definition of insanity, there is no reason to think that the same processes and personnel who have spent decades in government bureaucracies will be able to reform themselves without some outside help. The status quo won't shake up the status quo. We need an infusion of new ideas, personnel and leadership in our capital city. Specifically, we need to lean on one of America's great strengths and resources: our incredibly successful, world-leading private sector. American businesses are second to none. We need to tap into the insights, methods and expertise of our business leaders and technical experts to turn the government around. Thankfully, President Trump and his administration are doing just that. A number of the president's cabinet secretaries are Washington outsiders who bring heavyweight private sector resumes to their new roles. The same goes for key subcabinet posts. For example, President Trump's nominee to run the federal Office of Personnel Management is a venture capitalist and tech executive with a quarter century of high-stakes business leadership under his belt. The most notable place where the president has brought in fresh energy and ideas from the private sector is the Department of Government Efficiency. Everybody knows about its leader, the hugely successful and outspoken entrepreneur Elon Musk. But a wealth of other top tech talent is working away behind the scenes, helping to find new efficiencies, examples of waste to cut and opportunities to update and upgrade how our government works. The team includes the sharp, young engineers who have attracted political and press attention, but it also includes veteran executives and marquee leaders who have answered the call to serve. Tom Krause, CEO of Cloud Software Group, is helping reform the Treasury Department's ancient payment processes. Joe Gebbia, co-founder of Airbnb, is helping to digitize the tangled processes around federal retirements. All of us are lucky that such well-respected minds in business and management are helping refocus our government around stewarding funds wisely and getting results. This is a turnaround project like no other, and it needs all hands on deck. I had the privilege of serving on the U.S. House Energy and Commerce Committee during my tenure representing the Commonwealth of Pennsylvania. I saw firsthand the misuse of federal funds, the inefficiency of the bureaucracy and the blatant waste of taxpayer dollars. But making meaningful cuts in a smart, targeted way can be tricky business. We want to crack down on waste, fraud and overreach but preserve genuinely important programs that support hardworking families, encourage innovation in key fields like energy, national security and AI, and give taxpayers a strong return for their money. Separating the wheat from the chaff takes skilled analysis and strong, outcome-driven leadership. These are not virtues for which Washington is famous. Luckily, the business world has them in spades. Despite consternation from some in the media about bringing private-sector expertise into government, this is absolutely nothing new. High-profile businesspeople have served and advised presidential administrations of both parties, bringing their fresh perspectives to bear on problems that have stumped the permanent class inside Washington. President Obama brought General Electric CEO Jeff Immelt to lead an economic advisory board, along with entrusting the executive chairman of Alphabet, Eric Schmidt, to lead a major Pentagon innovation board. President Biden staffed his Council of Advisors on Science and Technology with a whole list of private sector leaders, including from tech giants Google, Microsoft and Nvidia. President Trump and DOGE are working to fix the broken systems our government relies on. They are absolutely right to call upon our country's deep well of human capital in the form of our top business leaders to do it. The American people have spoken, and they want significant and meaningful reform. A majority of Americans support DOGE's mission to increase accountability and enact long-lasting federal reforms. Already, thanks to DOGE's efforts, billions of dollars worth of savings have been found. But if we're actually going to redirect the slow-moving shipwreck of federal waste and budget deficits, these early efforts must only be the beginning. We need to keep drawing on outside perspectives and the business world's results-driven mindset to cut through the jungle of red tape and deliver meaningful results for Americans everywhere.
